<DOC>
	<DOCNO>NCT03006003</DOCNO>
	<brief_summary>The study conduct assess depressive symptom related marker postmenopausal female anti-osteoporosis treatment .</brief_summary>
	<brief_title>Osteoporosis Treatment Post-menopausal Women</brief_title>
	<detailed_description>Fracture one important complication female . Osteoporosis treat postmenopausal female due high risk fracture . Recently , many class medication develop prevent bone loss . Raloxifene , oral form anti-osteoporosis medication , report improved central nervous disorder . Therefore , study design assess depressive symptom related marker postmenopausal female anti-osteoporosis treatment .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<criteria>Postmenopausal female Osteoporosis Psychological disorder</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Raloxifene</keyword>
	<keyword>Central nervous disorder</keyword>
</DOC>